Revolutionary Nutraceutical 'AKTOCYTE' Launched to Aid Cancer Patients

The Department of Atomic Energy and IDRS Labs have launched 'AKTOCYTE,' a nutraceutical aimed at improving the quality of life for cancer patients undergoing radiotherapy. Approved by FSSAI, the supplement shows promising results, particularly in pelvic cancer patients, and is designed to support existing treatments.

The Department of Atomic Energy (DAE) in alliance with IDRS Labs has unveiled 'AKTOCYTE,' a groundbreaking food supplement aimed at boosting the quality of life for cancer patients undergoing radiotherapy.

This nutraceutical has gained approval from the Food Safety and Standards Authority of India (FSSAI), according to an official release.

Experts from Bhabha Atomic Research Centre, Mumbai; Advanced Centre for Training Research and Education in Cancer, Navi Mumbai; Tata Memorial Hospital, Mumbai; and officials from M/s IDRS Labs, who contributed to the tablet's development, attended the launch ceremony.

Dr. Sudeep Gupta, Director TMC, disclosed that the tablet's initial development efforts began some 25 years ago. AKTOCYTE tablets have shown exceptionally positive results, especially for pelvic cancer patients experiencing radiotherapy-induced side effects. Patients using AKTOCYTE tablets have exhibited remarkable recovery from radiotherapy-induced toxicity.

Intended as an adjuvant to cancer radiotherapy, as well as a regenerative nutraceutical, immunomodulator, and antioxidant, this tablet marks a significant stride in cancer care.

Dr. Gupta reiterated that AKTOCYTE is not a substitute for any existing cancer treatment and has been approved by FSSAI as a nutraceutical. He added the importance of conducting further studies to confirm its potential use as a drug for specific applications.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)